key topics
navigation
|
Why We Need A New Chronic Disease Paradigm
| | |
We live in a world dominated by chronic disease but continue to practice as if we are still dealing with acute illnesses. Anyone who works with arthritis patients can tell you the current system does not work. We reward the wrong things. We look for quick fixes and believe in false promises. We invest in the wrong technology. Moving to a system better suited to chronic disease care requires significant changes in thinking.1,2
The idea of prevention needs to be recast in terms of preventing the occurrence of expensive and disruptive exacerbations. Good care prevents the transition from impairment to disability and from disability to handicap. In the context of chronic diseases, the most preventable event is iatrogenic disease.
We must reexamine how we spend our time with patients. The heart of chronic disease management, as with geriatrics, is the principle of investing upfront with the expectation of recouping the investment with better results in the future. The current payment system does not support this approach. The idea of ordering patients to return for scheduled appointments should give way to an approach in which we see patients when their condition changes rather than just arbitrarily. Visits should be long enough to allow for an adequate assessment of the causes for the change in status. Patients staying the course need only short contacts, which can often be handled by other health care professionals. We must reexamine professional roles. Much of what has routinely been done by primary care physicians can be performed by nurse practitioners.3
Meaningful, active patient participation in their care is critical to chronic disease management. The efforts to empower patients have been encouraging but we need to form real partnerships between patients and clinicians.4 We need to teach patients how to make relevant observations of their status and what to do when the situation changes.
Accountability in chronic care must be expressed as the difference between actual and expected results. Unfortunately, the expected course is rarely shown. Accordingly, all one sees is a decline in the face of good care. Systems for showing the true benefit (expressed by this difference) are critical to developing support for investing in better chronic care.
Information systems are the critical technology for chronic disease care. We need to develop ways to deliver relevant information in a way that gets the attention of care providers. The current electronic medical record is not up to the task. We need an information system that is more structured and proactive.
Clinicians in medical care and long-term care need to agree on shared goals and communicate effectively. Most people are receiving long-term care because of serious underlying medical problems but long-term care means more than just attending to illnesses.
We must do more to bring the health care system into alignment with the epidemiological reality of chronic illness. Clinicians working in arthritis and rheumatology should be leading the charge. Randomized trials point to better ways to deliver chronic care.5 We typically think that better payment will solve the problem. Indeed, we worry about financing before we have a product worth buying. Changing the payment system is necessary but not sufficient. First, we must fix the infrastructure. Payment reform should reinforce the needed changes but will not bring them about on its own. |
1. Kane RL, Priester R, Totten AM. Meeting the Challenge of Chronic Illness. Baltimore: Johns Hopkins University Press; 2005.
2. Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. The Milbank Quarterly. 1996;74(4):511-543.
3. Mundinger M, Kane R, Lenz E, et al. Primary care outcomes in patients treated by nurse practitioners or physicians: A randomized trial. JAMA. 2000;283(1):59-68.
4. Lorig KR, Sobel DS, Stewart AL, et al. Evidence suggesting that a chronic disease self-management program can improve health status while reducing hospitalization: A randomized trial. Medical Care. 1999;37(1):5-14.
5. Boult C, Kane RL, Brown R. Managed care of chronically ill older people: The US experience. British Medical Journal. 2000;321:1011-1014. |
| Arthritis Practitioner - ISSN: 1 - Volume 2 - Issue 2 - March 2006 - Pages: 34 - | |
|
A complimentary CME Webcast Event
To register for this Web Archive program, click on Complimentary CME Webcast Event
This activity is for nurse practitioners, physician assistants, rheumatologists and internal medicine
physicians who treat patients with rheumatoid arthritis (RA).
Panelists/Lectures
"What You Should Know About Treating Early RA"
Nathan Wei, MD
Clinical Director
Arthritis and
Osteoporosis Center
Frederick, Md.
"A Closer Look At The Efficacy And Safety Of Combination Therapy With Anti-TNF Agents"
Philip Mease, MD
Clinical Professor
University of Washington
School of Medicine
Chief, Rheumatology Clinical Research
Swedish Hospital Medical Center
Seattle
"What The Studies Reveal About Emerging Therapies For RA"
Salahuddin Kazi, MD
Chief of Rheumatology
Presbyterian Hospital
Dallas,Tx.
This activity is supported by an educational grant from Genentech and Biogen Idec. The activity is sponsored by the North American Center for Continuing Medical Education (NACCME).
A complimentary CME Webcast Event
ON DEMAND
(Q&A with panelists to follow lectures)
To register for this Webcast program, click on Complimentary CME Webcast
This activity is geared to physicians, rheumatologists, nurses, physician assistants and nurse practitioners who treat rheumatoid arthritis.
Agenda And Faculty
“Treating RA: The Shift To A More Aggressive Therapeutic Approach”
Linda Davis, MHS, PA-C
Assistant Professor
University Of North Texas Health Science Center
“What The Literature Reveals About Combination Therapy”
Kevin M. Latinis, MD, PhD
Division of Allergy, Clinical Immunology and Rheumatology
University of Kansas Medical Center
“New Biologic DMARDs: Can They Have An Impact?”
Salahuddin Kazi, MD
Chief of Rheumatology
Presbyterian Hospital
Dallas, Texas
This activity is supported by an educational grant from Bristol-Myers Squibb. The activity is sponsored by the North American Center for Continuing Medical Education (NACCME).
A complimentary CME Web Archive Event
To register for this Web Archive program, click on Complimentary CME Web Archive Event
This activity is geared to physicians, nurses, physician assistants and nurse practitioners who treat osteoarthritis.
Agenda And Faculty
“A Closer Look At The Role Of Intraarticular Injections”
Frank Caruso, PA-C
Physician Assistant
Wake Forest University Baptist Medical Center
Winston-Salem, NC
“What The Literature Reveals About Viscosupplementation”
Nathan Wei, MD
Clinical Director
Arthritis and Osteoporosis Center
Frederick, MD
“Mastering The Technique Of Intraarticular Injections”
Mike Rudzinski, PA-C
Physician Assistant
Buffalo Veterans Affairs Medical Center
Buffalo, NY
This activity is supported by an educational grant from Genzyme. The activity is sponsored by the North American Center for Continuing Medical Education (NACCME).
A Complimentary CME Webcast Event
A Complimentary, On-Demand CME Webcast
To register for this Webcast program, click on Complimentary CME Webcast Event
This activity is geared to physicians, nurses, physician assistants and nurse practitioners who treat rheumatoid arthritis.
AGENDA and FACULTY
"Reviewing The Role of DMARDs In Treating RA"
Don Flinn, PA-C
Physician Assistant, McBride Clinic, Oklahoma City, Ok.
Vice-President, Society Of Physician Assistants In Rheumatology
"Assessing The Potential of Biologic Therapies"
Mark Genovese, MD
Associate Professor of Medicine
Division of Immunology And Rheumatology
Stanford University School Of Medicine
"What You Should Know About Infusion Therapy"
Nathan Wei, MD
Clinical Director
Arthritis and Osteoporosis Center
Frederick, Md.
This activity is supported by an educational grant from Bristol-Myers Squibb.
The activity is sponsored by the North American Center for Continuing Medical Education (NACCME).
Educational Monographs

In a CME/CE roundtable discussion, expert panelists review the subtypes of JIA, keys to patient adherence and insights on treatments ranging from NSAIDs and methotrexate to emerging biologic agents.
This CME monograph is supported by an educational grant from Abbott Laboratories. It is sponsored by the North American Center for Continuing Medical Education (NACCME).
|